课题基金 / 基金详情

Human Endocrine Cell Development

Human Endocrine Cell Development
人类内分泌细胞发育
批准号:
8456068
负责人:
NOAH Freeman SHROYER
金额:
$43.91万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-07 至 2017-02-28

项目摘要

项目成果

NOAH Freeman SHROYER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):在小鼠中,碱性螺旋-环-螺旋转录因子Neurogenin 3(NEUROG 3)对于胰腺和肠中内分泌谱系的发育至关重要。出生时具有NEUROG 3突变的人患有先天性肠内分泌细胞缺失(肠内分泌缺乏症)1,但令人惊讶的是具有正常的C肽水平并耐受葡萄糖静脉输注,这表明NEUROG 3功能不是人类胰腺β细胞发育所必需的。我们新的初步数据支持这一结论。本申请旨在探索人类明显缺乏胰腺内分泌表型的原因。我们将确定内分泌胰腺的发育是否是由于NEUROG 3活性的部分丧失而发生的,或者NEUROG 3功能不是人类内分泌胰腺发育所必需的。确定NEUROG 3的作用至关重要,因为它被认为是从人ES细胞或通过成体细胞类型新生产生胰腺内分泌细胞的治疗关键。鉴于携带NEUROG 3突变的患者组织的罕见性,不可能从机制上研究肠内分泌细胞发育与胰腺内分泌细胞发育差异的基础。为了能够进行这样的发育研究,我们建立了一种培养系统,其中人胚胎干细胞和诱导多能干细胞(统称为PSC)在体外有效地分化成胰腺或肠组织。我们用于PSC衍生的肠组织的新方法产生具有肠道的所有主要功能细胞类型的上皮,包括肠内分泌细胞。此外,我们已经能够敲低肠上皮中的NEUROG 3,导致人类肠内分泌细胞几乎完全丧失。我们将使用人PSC的胰腺和肠内分泌细胞的发育作为模型来鉴定调节人内分泌胰腺发育的NEUROG 3依赖性和独立性途径。我们将首先确定NEUROG 3水平对体外人PSC胰腺和肠道内分泌发育的影响。我们将通过观察NEUROG 3水平对已知靶点和新途径的影响,确定肠道和胰腺对NEUROG 3差异需求的分子基础。最后,我们将在体外和体内研究NEUROG 3水平对胰腺和肠细胞功能的影响。总之,我们提出的目标构成了人类胰腺和肠道发育过程中NEUROG 3前所未有的功能研究。我们的研究将明确确定NEUROG 3是否是胰腺与肠内分泌细胞发育所必需的,如果不需要,则确定补偿NEUROG 3缺失的分子途径。
英文摘要
DESCRIPTION (provided by applicant): In mice, the basic Helix-loop-helix transcription factor Neurogenin 3 (NEUROG3) is essential for development of the endocrine lineage in both the pancreas and the intestines. Humans born with NEUROG3 mutations suffer from congenital loss of enteroendocrine cells (enteric anendocrinosis) 1 but surprisingly had normal C- peptide levels and tolerate intravenous infusion of glucose, suggesting that NEUROG3 function is not required for pancreatic beta-cell development in humans. Our new preliminary data supports this conclusion. This application with explore the cause for the apparent lack of a pancreatic endocrine phenotype in humans. We will determine if endocrine pancreas development occurred due to a partial loss of NEUROG3 activity, or alternatively NEUROG3 function is not required development of human endocrine pancreas. Identifying the role of NEUROG3 is critical since it is considered a therapeutic linchpin for generating pancreatic endocrine cells from human ES cells or via neogenesis from adult cell types. Given the rarity of tissues from patients harboring NEUROG3 mutations, it has been impossible to mechanistically investigate the basis for this difference in intestinal versus pancreatic endocrine cell development. To enable such a developmental study, we have established a culture system whereby human embryonic and induced pluripotent stem cells (collectively called PSCs) are efficiently differentiated into eithe pancreatic or intestinal tissue in vitro. Our novel method for PSC-derived intestinal tissue generates an epithelium with all of the major functioning cell types of the gut, including enteroendocrine cells. Moreover we have been able to knock down NEUROG3 in the intestinal epithelium resulting in nearly complete loss of human enteroendocrine cells. We will use development of pancreatic and intestinal endocrine cells from human PSCs as a model to identify NEUROG3-dependent and independent pathways that regulate human endocrine pancreas development. We will first determine the impact of NEUROG3 levels on pancreatic and intestinal endocrine development from human PSCs in vitro. We will identify the molecular basis for the differential requirement for NEUROG3 between the gut and pancreas by looking at the effects of NEUROG3 levels on known targets and novel pathways. Lastly we will investigate the impact of NEUROG3 levels on pancreatic and intestinal cell function in vitro and in vivo. Together, our proposed aims constitute an unprecedented functional study of NEUROG3 during human pancreas and intestinal development. Our studies will unambiguously determine if NEUROG3 is required for the development of pancreatic versus intestinal endocrine cells and if it is not required, identify the molecular pathways that compensate for absence of NEUROG3.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of telomere-induced disease: Role of intestinal malabsorption, barrier dysfunction and dsybiosis.
  • 批准号:
    10454085
  • 项目类别:
  • 资助金额:
    $71.89万
  • 财政年份:
    2022
  • 负责人:
    NOAH Freeman SHROYER
  • 依托单位:
Mechanisms of telomere-induced disease: Role of intestinal malabsorption, barrier dysfunction and dsybiosis.
  • 批准号:
    10632001
  • 项目类别:
  • 资助金额:
    $64.89万
  • 财政年份:
    2022
  • 负责人:
    NOAH Freeman SHROYER
  • 依托单位:
The Gastrointestinal Experimental Model Systems (GEMS) Core
  • 批准号:
    10117232
  • 项目类别:
  • 资助金额:
    $17.6万
  • 财政年份:
    2020
  • 负责人:
    NOAH Freeman SHROYER
  • 依托单位:
Mechanisms of intestinal stem cell differentiation and plasticity.
  • 批准号:
    9788430
  • 项目类别:
  • 资助金额:
    $56.09万
  • 财政年份:
    2018
  • 负责人:
    NOAH Freeman SHROYER
  • 依托单位:
海外基金